Cyxone welcomes

Cyxone (publ), a biotech firm in autoimmune ailments, re-engages Professor Rikard Holmdahl as Scientific Advisor for the corporate’s initiatives in autoimmune ailments.

Rikard Holmdahl has lengthy established expertise and professional information in immunology and autoimmune ailments. Professor Holmdahl is one in every of Sweden’s main scientists in immunology who has contributed to very priceless insights into the mechanisms inflicting persistent inflammatory ailments equivalent to a number of sclerosis and rheumatoid arthritis. He has throughout his profession been acknowledged with a number of prestigious scientific prizes for his pioneering analysis.

Professor Holmdahl is a member of the Royal Swedish Academy of Sciences and has additionally been a part of the Nobel Meeting between 2014 and 2021. Since 2008, Holmdahl has led a world-leading staff of scientists in inflammatory ailments at Karolinska Institute (KI) and has been one of many main scientists behind the invention of Cyxone’s drug candidate rabeximod.

Professor Rikard Holmdahl feedback: “I’m trying ahead to persevering with following the thrilling growth of rabeximod and in the very best approach supporting Cyxone’s staff of their efforts to deliver this fascinating drug candidate to the market. Rabeximod is a novel molecule developed by Swedish scientists primarily based on the idea it may block irritation. Utilizing preclinical fashions, we later understood that it was environment friendly for therapy of arthritis, and we additionally bought some helpful concepts of its perform. On that foundation a medical trial was carried out which demonstrated a related therapeutic impact, however we additionally thought it might be additional improved by altering the therapy protocol, which Cyxone now’s exploring in a really fascinating approach.”

“It’s an honor that Professor Holmdahl now re-engages in Cyxone’s Scientific Advisory Board and actively demonstrates his nice curiosity to proceed to assist rabeximod within the growth of a therapy which has the potential to satisfy unmet medical wants for sufferers with rheumatoid arthritis. Rikard Holmdahl has been a priceless half in establishing the rabeximod mission from the beginning. He’s very educated within the processes inflicting the ailments the place we see alternatives to make use of rabeximod, and he additionally has a big established community within the scientific group which is extraordinarily priceless to an organization like Cyxone“, says Carl-Magnus Högerkorp, CEO of Cyxone.

Contact

Carl-Magnus Högerkorp, CEO
Tel: +46 (0)70 781 88 12
E mail: carl.hogerkorp@cyxone.com

About Cyxone

Cyxone AB (publ) (Nasdaq First North Development Market: CYXO) develops illness modifying therapies for ailments equivalent to rheumatoid arthritis and a number of sclerosis. Rabeximod is a Part 2 candidate drug being evaluated for the administration of rheumatoid arthritis. T20K is a Part 1 candidate drug for therapy of a number of sclerosis. Licensed Adviser is FNCA Sweden AB. For extra data, please go to www.cyxone.com

https://information.cision.com/cyxone/r/cyxone-welcomes-a-renewed-engagement-by-professor-rikard-holmdahl-as-scientific-advisor,c3878823

https://mb.cision.com/Important/16882/3878823/2440333.pdf

Source link